Amp Volatility Score
Catalyst Info & Data Links
TITLE: Seladelpar (MBX-8025) for Primary Biliary Cholangitis (PBC) - Phase 3
ClinicalTrial.gov (NCT03602560): ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
WHAT IS THE NEXT CATALYST EVENT?
Phase 3 Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
11-05-2020 2020 Third Quarter Financial Results
11-02-2020 CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020
MECHANISM OF ACTION
Seladelpar is uniquely suited as a potential treatment for inflammatory liver diseases. In the liver, PPARδ is expressed in multiple cell types including: hepatocytes, cholangiocytes, Kupffer cells and stellate cells. Preclinical and clinical data support its effect on regulating genes involved in bile acids synthesis, inflammation, fibrosis and lipid metabolism, storage and transport.
Updated by JM
CBAY, CymaBay Therapeutics, Primary Biliary Cholangitis (PBC), Seladelpar (MBX-8025), Liver Disease
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post